Browse DACT3

Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Basic function annotation.
> Subcellular Location, Domain and Function
> Gene Ontology
> KEGG and Reactome Pathway
> Subcellular Location, Domain and Function
 
Subcellular Location -
Domain PF15268 Dapper
Function

May be involved in regulation of intracellular signaling pathways during development. Specifically thought to play a role in canonical and/or non-canonical Wnt signaling pathways through interaction with DSH (Dishevelled) family proteins.

> Gene Ontology
 
Biological Process GO:0001558 regulation of cell growth
GO:0001837 epithelial to mesenchymal transition
GO:0006606 protein import into nucleus
GO:0006913 nucleocytoplasmic transport
GO:0010717 regulation of epithelial to mesenchymal transition
GO:0010719 negative regulation of epithelial to mesenchymal transition
GO:0016049 cell growth
GO:0016055 Wnt signaling pathway
GO:0017038 protein import
GO:0030111 regulation of Wnt signaling pathway
GO:0030178 negative regulation of Wnt signaling pathway
GO:0030308 negative regulation of cell growth
GO:0032386 regulation of intracellular transport
GO:0032387 negative regulation of intracellular transport
GO:0033157 regulation of intracellular protein transport
GO:0034504 protein localization to nucleus
GO:0035411 catenin import into nucleus
GO:0035412 regulation of catenin import into nucleus
GO:0035414 negative regulation of catenin import into nucleus
GO:0042306 regulation of protein import into nucleus
GO:0042308 negative regulation of protein import into nucleus
GO:0044744 protein targeting to nucleus
GO:0045926 negative regulation of growth
GO:0046822 regulation of nucleocytoplasmic transport
GO:0046823 negative regulation of nucleocytoplasmic transport
GO:0048762 mesenchymal cell differentiation
GO:0051051 negative regulation of transport
GO:0051169 nuclear transport
GO:0051170 nuclear import
GO:0051224 negative regulation of protein transport
GO:0060070 canonical Wnt signaling pathway
GO:0060485 mesenchyme development
GO:0060828 regulation of canonical Wnt signaling pathway
GO:0090090 negative regulation of canonical Wnt signaling pathway
GO:0090317 negative regulation of intracellular protein transport
GO:0198738 cell-cell signaling by wnt
GO:1900180 regulation of protein localization to nucleus
GO:1900181 negative regulation of protein localization to nucleus
GO:1902593 single-organism nuclear import
GO:1903533 regulation of protein targeting
GO:1903828 negative regulation of cellular protein localization
GO:1904589 regulation of protein import
GO:1904590 negative regulation of protein import
GO:1904950 negative regulation of establishment of protein localization
Molecular Function GO:0005080 protein kinase C binding
GO:0008013 beta-catenin binding
GO:0051018 protein kinase A binding
GO:0070097 delta-catenin binding
Cellular Component -
> KEGG and Reactome Pathway
 
KEGG -
Reactome -
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Literatures that report relations between DACT3 and anti-tumor immunity. The specific mechanism were also collected if the literature reports that a gene specifically promotes or inhibits the infiltration or function of T/NK cells.
> Text Mining
 

There is no record.
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content High-throughput screening data (e.g. CRISPR-Cas9, shRNA and RNAi) for T cell-mediated killing. Genetic screen techniques can identify mechanisms of tumor cell resistance (e.g., PTPN2) and sensitivity (e.g., APLNR) to killing by cytotoxic T cells, the central effectors of anti-tumor immunity. After comprehensively searching, eight groups of screening data sets were collected in the current database. In this tab, users can check whether their selected genes cause resistance or increase sensitivity to T cell-mediated killing in various data sets.
> High-throughput Screening
  Statistical results of DACT3 in screening data sets for detecting immune reponses.
PMID Screening System Cancer Type Cell Line Data Set Statistical Results Relation to immunity
29301958CRISPR-Cas9 melanomaB16F10Pmel-1 T cell NA/NSNA/NS
29301958CRISPR-Cas9 melanomaB16F10OT-1 T cell NA/NSNA/NS
28783722CRISPR-Cas9 melanomaMel6242CT-CRISPR NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX+Anti-PD1 NA/NSNA/NS
28723893CRISPR-Cas9 melanomaB16GVAX NA/NSNA/NS
25691366RNAiBreast cancerMCF7Luc-CTL assay NA/NSNA/NS
24476824shRNAmelanomaB16Primary screen NA/NSNA/NS
24476824shRNAmelanomaB16Secondary screen NA/NSNA/NS
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Transcriptomic and genomic profiling of pre-treated tumor biopsies from responders and non-responders to immunotherapy. These data were used to identify signatures and mechanisms of response to checkpoint blockade (e.g., anti-PDL1 and anti-PD1). One example is that mutations in the gene PBRM1 benefit clinical survival of patients with clear cell renal cell carcinoma. After comprehensively searching, we collected 5 and 6 of transcriptomic and genomic data sets, respectively. In this tab, users can check whether their selected genes have significant difference of expression or mutation between responders and non-responders in various data sets.
> Expression difference between responders and non-responders
> Mutation difference between responders and non-responders
> Expression difference between responders and non-responders
 
Points in the above scatter plot represent the expression difference of DACT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes Log2 (Fold Change) P value Anno
126997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)1412-1.1190.0401
226997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)65-1.9170.0924
326997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)87-0.5530.623
428552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916-0.6460.3
528552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59-0.0970.959
628552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47-1.3410.559
729033130MelanomaallAnti-PD-1 (nivolumab) 2623-0.030.948
829033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 1511-0.4780.585
929033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 11120.4920.594
1029301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 480.370.629
1129301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 2001
1229301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 280.8970.366
1329443960Urothelial cancerallAnti-PD-L1 (atezolizumab) 68230-0.440.0371
> Mutation difference between responders and non-responders
 
Points in the above scatter plot represent the mutation difference of DACT3 in various data sets.
No PMID Cancer type Group Drug # Res # NRes % Mut/Res % Mut/NRes % Diff (R vs NR) Pval Anno
125765070Non-small cell lung cancer (NSCLC)allAnti-PD-1 (pembrolizumab) 14170001
225765070Non-small cell lung cancer (NSCLC)smokingAnti-PD-1 (pembrolizumab) 1030001
325765070Non-small cell lung cancer (NSCLC)non-smokingAnti-PD-1 (pembrolizumab) 4140001
426359337MelanomaallAnti-CTLA-4 (ipilimumab) 277301.4-1.41
526359337MelanomaBRAFiAnti-CTLA-4 (ipilimumab) 0140001
626359337Melanomanon-BRAFiAnti-CTLA-4 (ipilimumab) 275901.7-1.71
726997480MelanomaallAnti-PD-1 (pembrolizumab and nivolumab)21170001
826997480MelanomaMAPKiAnti-PD-1 (pembrolizumab and nivolumab)860001
926997480Melanomanon-MAPKiAnti-PD-1 (pembrolizumab and nivolumab)13110001
1028552987Urothelial cancerallAnti-PD-L1 (atezolizumab) 916012.5-12.50.52
1128552987Urothelial cancersmokingAnti-PD-L1 (atezolizumab) 59011.1-11.11
1228552987Urothelial cancernon-smokingAnti-PD-L1 (atezolizumab) 47014.3-14.31
1329033130MelanomaallAnti-PD-1 (nivolumab) 38272.602.61
1429033130MelanomaNIV3-PROGAnti-PD-1 (nivolumab) 22134.504.51
1529033130MelanomaNIV3-NAIVEAnti-PD-1 (nivolumab) 16140001
1629301960Clear cell renal cell carcinoma (ccRCC)allAnti-PD-1 (nivolumab) 11130001
1729301960Clear cell renal cell carcinoma (ccRCC)VEGFRiAnti-PD-1 (nivolumab) 610001
1829301960Clear cell renal cell carcinoma (ccRCC)non-VEGFRiAnti-PD-1 (nivolumab) 5120001
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between abundance of tumor-infiltrating lymphocytes (TILs) and expression, copy number, methylation, or mutation of DACT3. The immune-related signatures of 28 TIL types from Charoentong's study, which can be viewed in the download page. For each cancer type, the relative abundance of TILs were inferred by using gene set variation analysis (GSVA) based on gene expression profile. In this tab, users can examine which kinds of TILs might be regulated by the current gene.
> Lymphocyte
 
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between three kinds of immunomodulators and expression, copy number, methylation, or mutation of DACT3. These immunomo-dulators were collected from Charoentong's study. In this tab, users can examine which immunomodulators might be regulated by DACT3.
> Immunoinhibitor
> Immunostimulator
> MHC molecule
> Immunoinhibitor
 
> Immunostimulator
 
> MHC molecule
 
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Relations between chemokines (or receptors) and expression, copy number, methylation, or mutation of DACT3. In this tab, users can examine which chemokines (or receptors) might be regulated by the current gene.
> Chemokine
> Receptor
> Chemokine
 
> Receptor
 
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Distribution of DACT3 expression across immune and molecular subtypes.
> Immune subtype
> Molecular subtype
> Immune subtype
 
> Molecular subtype
 
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Associations between DACT3 and clinical features.
> Overall survival analysis
> Cancer stage
> Tumor grade
> Overall survival
 
> Stage
 
> Grade
 
Summary
SymbolDACT3
Namedishevelled-binding antagonist of beta-catenin 3
Aliases MGC15476; DAPPER3; RRR1; arginine rich region 1; dapper, antagonist of beta-catenin, homolog 3 (Xenopus laev ......
Chromosomal Location19q13.32
External Links HGNC, NCBI, Ensembl, Uniprot, GeneCards
Content Drugs targeting DACT3 collected from DrugBank database.
> Drugs from DrugBank database
 

There is no record.